The PneumoSIP System has been conceived to provide a fast, accurate, simple and cost-efficient solution for the diagnostic of Pneumonia.

WHY PNEUMONIA
WHY PNEUMONIA

WHY PNEUMONIA?

Community-acquired pneumonia (CAP), together with lower respiratory tract infections, is the fourth most common cause of death in adults (reaching 90% in people over 65) and the leading cause of death in children under 5 years. The annual incidence of CAP in Europe is expected to be around 3,4 million cases and it represents an important burden on healthcare resources. The associated annual cost in Europe is estimated to be 10€ billion, mainly due to hospitalisation of late diagnosed patients.

EARLY DIAGNOSTIC IS KEY

EARLY DIAGNOSTIC IS KEY

Late Diagnostic is one of the main causes of patient deterioration. PneumoSIP surpasses the existing methods by reducing time-to-result and provides information about the best line of treatment.

EARLY DIAGNOSTIC IS KEY

ADVANTAGES

The PneumoSIP System combines a one-stop diagnostic platform and an amplification-based test to provide a fast, accurate, simple and cost-efficient solution for the diagnostic of Pneumonia.

Fast quantification
FAST QUANTIFICATION OF THE MAIN AETIOLOGIES
IDENTIFICATION OF ANTIBIOTIC RESISTANCE
IDENTIFICATION OF ANTIBIOTIC RESISTANCE
DIAGNOSTIC OF CO-INFECTIONS
DIAGNOSTIC OF CO-INFECTIONS
FULLY AUTOMATED, EASY-TO-USE
FULLY AUTOMATED, EASY-TO-USE
USE IN LABORATORIES
USE IN LABORATORIES

USE IN LABORATORIES

The PneumoSIP system can be operated by qualified personnel, both in the microbiology and the ER laboratory.

USE IN ER/ICU
USE IN ER/ICU

USE IN ER/ICU

Due to its simple operation and high level of automation, the PneumoSIP system can also be used by trained nurses, both at ER and ICU.

EU SUPPORT

Eu support

PNEUMOSIP IS AN EU-ENDORSED PRODUCT

AlphaSIP is a winner of the 2015 European Commission’s SME Instrument, which promotes the development of Europe’s best and most innovative SMEs. This novel funding scheme helps high-potential SMEs to develop groundbreaking innovative ideas for products, services or processes that are ready to face global market competition. The SME Instrument has opened new possibilities for AlphaSIP, greatly accelerating the development of our new product range and increasing our chances of succeeding in the medical market.

Thanks to this award, AlphaSIP will receive 3,4M € to complete the development of PneumoSIP, our amplification-based pneumonia kit and MultySIP, its associated one-stop diagnostic platform. The development phase is expected to end in 24 months, after clinical validation, making both elements ready for commercialization.

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 685052

PARTNER WITH US

PARTNER WITH US

With the PneumoSIP System, AlphaSIP strives to create a new standard for amplification, and antibody-based assays. Its design, suitable for various settings and healthcare professionals, enables its use for the diagnostic of a wide range of pathogens and diseases.

AlphaSIP welcomes developers and commercializers of molecular diagnostics kits to co-expand MultySIP’s pipeline. Please, contact us for further information about partnering possibilities.

go to top